Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 674 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... January 31, 2022 For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 Foodie Fridays: Farmer’s Market Finds July 16, 2021 SABCS 2021: New Research and Updates in Breast Cancer Treatment and... January 20, 2022 Load more HOT NEWS DeFi Trial: Smart Design and Impressive Results For the Benefit of... European Lung Cancer Congress 2024 Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Enzalutamide
